JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer-Reference-Cited by-同舟云学术

JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer

Published:2020-02 Issue: Volume:126 Page:125-135
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bagratuni Tina,Mavrianou Nefeli,Gavalas Nikolaos G.,Tzannis Kimon,Arapinis Calliope,Liontos Michael,Christodoulou Maria I.,Thomakos Nikolaos,Haidopoulos Dimitrios,Rodolakis Alexandros,Kastritis Efstathios,Scorilas Andreas,Dimopoulos Meletios A.,Bamias Aristotle

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Ovarian carcinoma diagnosis;Goff;Cancer,2000

2. Cancer statistics;Siegel;CA Cancer J Clin,2014

3. The Myc oncoprotein as a therapeutic target for human cancer;Vita;Semin Cancer Biol,2006

4. Knockdown of c-Myc inhibits cell proliferation by negatively regulating the Cdk/Rb/E2F pathway in nasopharyngeal carcinoma cells;Niu;Acta Biochim Biophys Sin,2015

5. c-MYC: more than just a matter of life and death;Pelengaris;Nat Rev Cancer,2002

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC;Cell Communication and Signaling;2024-08-27

2. In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors;OncoImmunology;2024-07-18

3. CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer;Functional & Integrative Genomics;2024-07-12

4. A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity;iScience;2024-07

5. PAX2 mediated upregulation of ESPL1 contributes to cisplatin resistance in bladder cancer through activating the JAK2/STAT3 pathway;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-04-04